Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aptevo Therapeutics Inc (APVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 49,918
  • Shares Outstanding, K 22,690
  • Annual Sales, $ 14,660 K
  • Annual Income, $ 6,970 K
  • 36-Month Beta 2.06
  • Price/Sales 3.50
  • Price/Cash Flow N/A
  • Price/Book 1.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.56
  • Number of Estimates 2
  • High Estimate -0.53
  • Low Estimate -0.60
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.10 +4.76%
on 12/07/18
3.65 -39.73%
on 11/09/18
-1.27 (-36.60%)
since 11/07/18
3-Month
2.10 +4.76%
on 12/07/18
5.32 -58.65%
on 09/10/18
-2.98 (-57.53%)
since 09/07/18
52-Week
2.10 +4.76%
on 12/07/18
6.35 -65.35%
on 05/17/18
-1.57 (-41.64%)
since 12/07/17

Most Recent Stories

More News
Aptevo Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference

Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that management will be presenting at the 30 Annual Piper...

APVO : 2.20 (-2.65%)
Aptevo Therapeutics Reports Third Quarter 2018 Financial Results

Achieves 132% Increase in IXINITY Quarterly Net Revenue Year-Over-Year

APVO : 2.20 (-2.65%)
Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting

Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, and Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology...

APVO : 2.20 (-2.65%)
Aptevo Therapeutics Announces Expanded Growth Initiatives for IXINITY

Plans to Introduce 3000 IU IXINITY Assay for Enhanced Patient Convenience

APVO : 2.20 (-2.65%)
Market Trends Toward New Normal in Aptevo Therapeutics, Bottomline Technologies, Allete, Air Lease, The Goodyear Tire & Rubber, and EastGroup Properties -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Aptevo Therapeutics Inc....

EPAY : 50.20 (-1.93%)
APVO : 2.20 (-2.65%)
ALE : 81.03 (+0.20%)
AL : 36.32 (-2.05%)
GT : 22.12 (-2.08%)
EGP : 100.43 (-1.24%)
Aptevo Therapeutics to Present at the Ladenburg Thalmann 2018 Healthcare Conference

Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that management will be presenting at the Ladenburg Thalmann...

APVO : 2.20 (-2.65%)
Here's Why Momentum Investors Will Love Aptevo Therapeutics Inc. (APVO)

Does Aptevo Therapeutics Inc. (APVO) have what it takes to be a top stock pick for momentum investors? Let's find out.

APVO : 2.20 (-2.65%)
Wired News - Arrowhead Pharma Presented Preclinical Data on Expanding Pipeline of RNAi Therapeutics for Cardiometabolic Diseases

Stock Monitor: Aptevo Therapeutics Post Earnings Reporting

ARWR : 13.13 (-3.67%)
APVO : 2.20 (-2.65%)
Aptevo Therapeutics Reports First Quarter 2018 Financial Results

Almost Doubles Year-Over-Year IXINITY Quarterly Revenue

APVO : 2.20 (-2.65%)
New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 Presented by Aptevo Therapeutics and Alligator Bioscience at Prominent Industry Conferences

ALG.APV-527 is Designed to Strategically Target and Engage the Immune System for the Potential Treatment of Multiple Solid Tumor Indications

APVO : 2.20 (-2.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade APVO with:

Business Summary

Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics...

See More

Key Turning Points

2nd Resistance Point 2.45
1st Resistance Point 2.33
Last Price 2.20
1st Support Level 2.09
2nd Support Level 1.97

See More

52-Week High 6.35
Fibonacci 61.8% 4.73
Fibonacci 50% 4.22
Fibonacci 38.2% 3.72
Last Price 2.20
52-Week Low 2.10

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar